Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Bukwang expanded the partnership of ‘Aprovel and CoAprovel’ to General Hospitals

[January 04, 2022]

Bukwang Pharmaceutical(CEO Yoo Hee Won) announced that they made a contract with Sanofi-Aventis Korea on partnership expansion about sales-marketing of Aprovel(ingredient : irbesartan) and CoAprovel(ingredient : irbesartan+hydrochlorothiazide). The channel of the products is going to expand to not only local clinics but general hospitals. Since Jan. of 2020, Bukwang and Sanofi-Korea have collaborated with sales and marketing of the products. Sanofi-Korea have taken responsibility for general hospitals' sales and marketing and Bukwang...

R&D

Bukwang expanded the partnership of ‘Aprovel and CoAprovel’ to General Hospitals

[January 04, 2022]

Bukwang Pharmaceutical(CEO Yoo Hee Won) announced that they made a contract with Sanofi-Aventis Korea on partnership expansion about sales...

COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange...

Conterapharma
콘테라로고.jpg

Unlocking science for treating neurological disorders

   

Discover Bukwang

PRODUCTS
main_cg.jpg
|    ​Korean    |